COMMUNIQUÉ DE PRESSE publié le 19/01/2024 à 14:40, il y a 1 année 10 mois United Health Products Reports on FDA Application Status United Health Products (UEEC) reports on the receipt and review of final reports on product sterilization and stability testing for its hemostatic gauze as part of its FDA application process. The reported data on the efficacy of the proposed radiation sterilization protocol were well within acceptable bioburden levels for Class III products, and the company will proceed with final drafting of the PMA documentation for submission. The press release raises awareness about the company's ongoing FDA application status and its pursuit of approval for its hemostatic products. United Health Products UEEC FDA Application Status Hemostatic Gauze Premarket Approval Application
Publié le 04/12/2025 à 18:14, il y a 12 heures 57 minutes Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 11 minutes Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 11 minutes Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 13 heures 26 minutes Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 13 heures 26 minutes MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Publié le 05/12/2025 à 02:35, il y a 4 heures 36 minutes Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 01:00, il y a 6 heures 11 minutes BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 6 minutes BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 11 minutes NXT Energy Solutions Completes Data Acquisition for SFD Survey
Publié le 05/12/2025 à 07:00, il y a 11 minutes Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Publié le 05/12/2025 à 03:30, il y a 3 heures 41 minutes CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 7 heures 21 minutes EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 10 heures 46 minutes Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 10 heures 56 minutes Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025